Please login to view this media
- Talk
- 22/09/2021
- UK
The Re-Infection Rate Following 2 Stage Revision Knee Arthroplasty for Peri-Prosthetic Joint Infection: A Retrospective Review of 198 Patients
Description
The video transcript begins with an introduction by Lesley Kerwin, a journalist, discussing unproven treatments at a conference before handing over to Leela Biant. Biant acknowledges Kerwin's insights on current practices and invites Andrew McCaskey, a professor of orthopedics in Cambridge, to present evidence-based treatments, particularly those related to osteoarthritis. McCaskey emphasizes the importance of understanding the disease's progression, highlighting that osteoarthritis affects over eight million people in the UK and poses significant challenges, especially in its earlier stages where treatment options are limited.
He notes the need for effective approaches for patients aged 45-64, who represent a critical demographic with unmet needs. McCaskey explains that while joint replacement is successful for end-stage osteoarthritis, there's a substantial opportunity to intervene at earlier disease stages. He discusses the diverse phenotypes of osteoarthritis, indicating the disease's complexity, and outlines two main strategies for cell therapy: exogenous cell-based therapies, which involve administering cells as treatments, and targeting the body’s own endogenous populations to promote healing.
The discussion suggests that the use of stem cells could lead to better outcomes for osteoarthritis, particularly through advanced diagnostic methods and targeted treatments that address the varied manifestations of the disease.